UPS - LEIDER IST IHR BROWSER VERALTET!

Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

LEAP THERAPEUTICS nach der KE 2019

Seite 1 von 2
neuester Beitrag: 15.11.19 10:47
eröffnet am: 03.02.19 23:05 von: centsucher Anzahl Beiträge: 30
neuester Beitrag: 15.11.19 10:47 von: Vassago Leser gesamt: 3011
davon Heute: 2
bewertet mit 0 Sternen

Seite: Zurück 1 | 2 Weiter  

2794 Postings, 2171 Tage centsucherLEAP THERAPEUTICS nach der KE 2019

 
  
    
03.02.19 23:05

https://www.leaptx.com/


LEAP THERAPEUTICS, INC.

6,571,428 Shares of Common Stock

and Warrants to Purchase up to 6,571,428 Shares of Common Stock

https://www.sec.gov/Archives/edgar/data/1509745/...a2237643z424b5.htm

 
Seite: Zurück 1 | 2 Weiter  
4 Postings ausgeblendet.

2794 Postings, 2171 Tage centsucher.......

 
  
    
08.03.19 13:45
Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer

https://www.ariva.de/news/...nt-at-the-society-of-gynecologic-7455424

 

2794 Postings, 2171 Tage centsucherPerf. seit Threadbeginn: +16,67%

 
  
    
09.03.19 19:50
1,75$ Jetzt ist der Aktienpreis der letzten KE erreicht.  

2794 Postings, 2171 Tage centsucherPerf. seit Threadbeginn: +28,67%

 
  
    
12.03.19 15:24

2794 Postings, 2171 Tage centsucherPerf. seit Threadbeginn: +40,67%

 
  
    
12.03.19 17:08

2794 Postings, 2171 Tage centsucherPerf. seit Threadbeginn: +50,00%

 
  
    
12.03.19 18:16

2794 Postings, 2171 Tage centsucherStocke heute wieder auf.

 
  
    
14.03.19 14:51

2794 Postings, 2171 Tage centsucher2,01 $ +8,65% Perf. seit Threadbeginn: +34,00%

 
  
    
15.03.19 16:42
OK, jetzt nerve ich nicht weiter !  

2794 Postings, 2171 Tage centsucherEiner geht noch! :-))))

 
  
    
15.03.19 21:36
Perf. seit Threadbeginn:   +57,00%
Mein Ziel ist erreicht! Gewinne lasse ich laufen. Man soll ja nicht zu gierig sein!;-)))  

2794 Postings, 2171 Tage centsucherSociety of Gynecologic Oncology 50th Annual Meetin

 
  
    
18.03.19 21:47

the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer.
https://www.ariva.de/news/...esents-at-society-of-gynecologic-7470993

Poster https://docs.wixstatic.com/ugd/...03e4ba126f3464d9a0d078841bea21b.pdf


 

2794 Postings, 2171 Tage centsucherQ4 + Clinical Update

 
  
    
01.04.19 23:58
Leap Therapeutics Reports Clinical Update and 2018 Financial Results


Leap believes that its current cash and the expected receipt of research and development tax incentives will be sufficient to fund its operating expenses into the second quarter of 2020.

As of March 26, 2019 there were 22,260,301 outstanding shares of the registrant's common stock


https://www.ariva.de/news/...inical-update-and-2018-financial-7501801

https://investors.leaptx.com/node/7376/html

 

2794 Postings, 2171 Tage centsucherProspektnachtrag

 
  
    
05.04.19 19:22

Über die max. Aktienanzahl die von Leap verkauft werden dürfen.

https://investors.leaptx.com/node/7386/html

 

2794 Postings, 2171 Tage centsuchercorporate overview at ..............

 
  
    
05.04.19 19:29

Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference

CAMBRIDGE, Mass., April 3, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the 2019 Needham & Company 18th Annual Healthcare Conference, being held in New York City on April 9-10, 2019.

https://investors.leaptx.com/news-releases/...ham-company-18th-annual

 

2794 Postings, 2171 Tage centsucheraus dem Q4 18

 
  
    
05.04.19 20:40

-2019 finanziert!


We expect that our cash and cash equivalents of $16.3 million at December 31, 2018, together with the net proceeds from the February 2019 Public Offering of $12.1 million and the receipt of $0.8 million of research and development tax incentive payments from the Commonwealth of Australia as a result of the 2018 research and development activities of our Australian subsidiary, HealthCare Pharmaceuticals Pty Ltd, will be sufficient to fund our operating expenses for at least the next 12 months from issuance of the financial statements included in this Annual Report on Form 10-K


 

2794 Postings, 2171 Tage centsucherCompany Overview April 2019

 
  
    
10.05.19 20:46

DKN-01

Combination with KEYTRUDA®

?Enrollment complete: 52 PD-1/PD-L1 naïve patients

?Mature data Q3 2019?Clinical outcomes in GEJ/Gastric patients

?Enabling biomarkers --DKK1, PD-L1

Monotherapy and Combination with paclitaxel

?78 patients enrolled across 4 treatment arms

?Updated efficacy data Q3 2019

?Enabling biomarkers ?activating Wntpathway mutations, DKK1

TRX518

Combination with KEYTRUDA®/OPDIVO

?12 patients enrolled in Keytruda expansion, 20 total expected in Q2 2019

?Efficacy data Q4 2019

https://docs.wixstatic.com/ugd/c343d0_8716992ddbf44ecbaf4474ebc3d8f46a.pdf


 

2794 Postings, 2171 Tage centsucherAus dem Q1

 
  
    
21.05.19 19:02
--22,260,301 and 14,703,159 shares issued and outstanding as of March 31, 2019 and December 31, 2018

Der Anstieg der Aktien ist durch die Feb.2019 KE (Rund 7,5 Mio Aktien zu 1,75$ und 7,5 Mio Warrants mit einem Ausgabepreis von 1,95$)

--Rund 22 Mio$ cash
--Verbrennen ca. 8-9 Mio im Q
--MK 32,5 Mio (21.5.19)
-- Warants
2,758,094         $ 1.75
7,557,142         $ 1.95
https://investors.leaptx.com/node/7416/html

Company Overview Mai19
https://docs.wixstatic.com/ugd/...6f10968328346de9817bc80ea16051d.pdf

Pipeline
https://www.leaptx.com/our-pipeline  

2794 Postings, 2171 Tage centsucherQ3 rückt näher!

 
  
    
21.06.19 13:54
DKN-01

Combination with KEYTRUDA®

?Enrollment complete: 52 PD-1/PD-L1 naïve patients

?Mature data Q3 2019?Clinical outcomes in GEJ/Gastric patients

?Enabling biomarkers --DKK1, PD-L1

Monotherapy and Combination with paclitaxel

?78 patients enrolled across 4 treatment arms

?Updated efficacy data Q3 2019

?Enabling biomarkers ?activating Wntpathway mutations, DKK1  

2794 Postings, 2171 Tage centsucherSEC Filings zu den Purchase Agreements

 
  
    
12.07.19 14:26
Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital
https://www.ariva.de/news/...common-stock-purchase-agreements-7696546

424B5         https://investors.leaptx.com/node/7511/html
8K                https://investors.leaptx.com/node/7506/html  

2794 Postings, 2171 Tage centsucher....

 
  
    
25.07.19 16:52
Leap Therapeutics to Host Conference Call to Provide DKN-01 Program Update

https://www.ariva.de/news/...onference-call-to-provide-dkn-01-7727054

 

2794 Postings, 2171 Tage centsucherOK, ist halt so.

 
  
    
06.08.19 16:14

https://www.ariva.de/news/...ical-results-for-the-combination-7752548
The combination of DKN-01 and Keytruda in GEJ/GC patients demonstrated improved outcomes in patients whose tumors are DKK1-high and who were PD-1/PD-L1 naïve. DKK1-high patients experienced over 22 weeks median PFS and nearly 32 weeks OS, with a 50% ORR and 80% DCR in ten evaluable patients. DKK1-low patients experienced nearly 6 weeks median PFS and over 17 weeks OS, with a 20% DCR in fifteen evaluable patients.

PD-L1 Combined Positive Scores (CPS) did not predict efficacy on the combination of DKN-01 plus Keytruda. In multi-variate analysis, DKK1-high status correlated with longer PFS independent of PD-L1 CPS scores. One-third of patients in the study were DKK1-high.

Among the six GEJ/GC patients who were refractory to PD-1/PD-L1 therapy, three DKK1-high patients had a best response of stable disease, whereas the three patients with DKK1-low tumors had progressive disease.  

4466 Postings, 910 Tage VassagoLPTX 1,19$

 
  
    
07.10.19 12:51

4466 Postings, 910 Tage VassagoLPTX 0,63$ (-45%)

 
  
    
15.11.19 10:47

Zahlen für Q3/19

  • keine Umsätze
  • Verlust 8 Mio. $
  • Cash 10 Mio. $
  • MK 14 Mio. $
  • Depriorisierung von TRX518 zugunsten von DKN-01

https://investors.leaptx.com/news-releases/...-2019-financial-results

https://seekingalpha.com/news/...cs-bails-2-program-shares-43-percent

 

Seite: Zurück 1 | 2 Weiter  
   Antwort einfügen - nach oben